^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor

Published date:
11/13/2019
Excerpt:
We identified 116 mRCC patients who were administered sunitinib or sorafenib...Patients with low PBRM1 expression had significantly shorter median PFS (9 vs 26 months, P < 0.001) and OS (21 vs 44 months, P < 0.001) than those with high expression. The expression of PBRM1 could be a significant prognostic factor for mRCC patients treated with targeted therapy...
DOI:
10.1007/s10147-019-01564-1